3 Reasons Celgene Is a Buy

From the near to long-term there are many chapters left in Celgene's growth story.

Jun 2, 2014 at 6:30PM

Celgene (NASDAQ:CELG) was the subject of a recent downgrade from "overweight" to "neutral" by JPMorgan. Analysts didn't cite new concerns, but that won't stop media from speculating. In the face of uncertainty now is a great time to revisit the bull argument for the company.

Its lead program is going strong and climbing. Recent approvals position Celgene for sustained growth, and the company's adept use of cash is strengthening its market position.

Lead product growth
Revlimid sales have been growing steadily since it hit the U.S. market in 2006, and Celgene estimates $4.9 billion to $5 billion in Revlimid revenue for this year. While analyst estimated peak sales of $11 billion by 2021 seems fantastic, it isn't impossible. Several opportunities exist that would help it reach that peak and should play out over the next twelve months. Late-stage trials to support expansions into lymphoma are under way, and applications for treatment of newly diagnosed multiple myeloma are pending in the U.S. and EU. 

While the Revlimid performance has been outstanding, competition is getting stronger. Johnson & Johnson's (NYSE:JNJ) Velcade recently won a recommendation for first-line treatment of multiple myeloma in some circumstances from the UK's National Institute for Health and Care Excellence. Celgene has tussled with the cost-conscious committee over Revlimid with less success.

Increasingly, austere government payers across the EU are eager to avoid Revlimid's hefty price tag. Velcade's low price appears to be helping it gain share of the multiple myeloma market as first quarter sales rose 18% to $408 million.

The replacements
While Celgene continues expanding Revlimid, it's also feverishly working to fill the gap its eventual exclusivity loss will leave on the company's income statement. So far, the effort is going well. Last year's launch of multiple myeloma therapy Pomalyst was one of the industry's most successful. Sales of the therapy hit $305 million in 2013, and $136 million in the first quarter of this year.

Sales of Pomalyst have been pretty solid considering it ran headfirst into competition with Amgen's (NASDAQ:AMGN) proteasome inhibitor Kyprolis. Kyprolis won approval in July 2012, giving it a 6-month head start, but it appears Pomalyst is steadily outpacing its rival, as Amgen recorded just $68 million in first quarter Kyprolis sales -- but of course you'll still want to keep an eye on both drugs' performance going forward.

After enjoying incredible success in oncology, Celgene is now successfully expanding into immune disorders. In March, the FDA approved Otezla for the treatment of psoriatic arthritis, a relatively uncommon indication. It's currently under review for the much larger plaque psoriasis indication with a decision likely before the end of the year. If approved, Celgene's all-oral therapy's convenience may win over some share from drugs like Humira.

Acquisition history
Otezla and Pomalyst are likely to do well, but Celgene must continue adding to its pipeline. Luckily, the amount of money Celgene generates beyond what's necessary to maintain and expand its asset base -- called free cash flow -- is an executive's dream come true.

CELG Free Cash Flow (TTM) Chart

Source: Celgene free cash flow data by YCharts.

Over the past four quarters, Celgene has generated about $2.3 billion in free cash flow and is sitting on over $5 billion in cash..

Investors will be happy to know that Celgene has a history of investing wisely. The 2008 purchase of Pharmion for about $2.9 billion added Vidaza to the company's blood cancer lineup. Annual sales of the chemotherapy agent peaked at $823 million in 2012 before generic competition entered the U.S. market last September.

The 2010 acquisition of Abraxis -- also for $2.9 billion -- brought Abraxane into the fold. Sales of the injectable mitotic inhibitor are growing fast, with first quarter sales up 50.6% year over year to $184.8 million.

Final thoughts
What I like most about Celgene is the way it refit Thalomid for the multiple myeloma market, then successfully launched improvements in the form of Revlimid and Pomalyst. Successfully marketing Vidaza and Abraxane post-acquisition is another big feather in the company's cap. Past history doesn't necessarily predict future results, but it's a good start. With the amount of cash Celgene is generating, it will be interesting to see what it does next. 

Speaking of investments to watch, did you know that Warren Buffett just bought nearly 9 million shares of this company?
Imagine a company that rents a very specific and valuable piece of machinery for $41,000 per hour (That's almost as much as the average American makes in a year!). And Warren Buffett is so confident in this company's can't-live-without-it business model, he just loaded up on 8.8 million shares. An exclusive, brand-new Motley Fool report details this company that already has over 50% market share. Just click HERE to discover more about this industry-leading stock... and join Buffett in his quest for a veritable landslide of profits!

Cory Renauer has no position in any stocks mentioned. The Motley Fool recommends Celgene and Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers